Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
Other Sizes |
|
ln Vitro |
BPH-1358 is the most effective inhibitor of Staphylococcus aureus UPPS (SaUPPS) and Escherichia coli UPPS (EcUPPS), having an IC50 of 110 nM. With EC50s of 300 nM and 290 nM, respectively, BPH-1358 targets Staphylococcus aureus and Escherichia coli[1].
|
---|---|
ln Vivo |
BPH-1358 shows in vivo action against Staphylococcus aureus (20/20 mice survive an intraperitoneal infection scenario with MRSA strains) [1].
|
References |
[1]. Zhu W, et al. Antibacterial drug leads: DNA and enzyme multitargeting. J Med Chem. 2015 Feb 12;58(3):1215-27.
[2]. Liu YL, et al. Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries. ACS Med Chem Lett. 2015 Jan 29;6(3):349-54. |
Molecular Formula |
C32H28N6O2
|
---|---|
Molecular Weight |
528.61
|
Exact Mass |
528.2274
|
CAS # |
5352-53-4
|
Related CAS # |
BPH-1358 free base;801985-13-7;BPH-1358 mesylate
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C(C1C([H])=C([H])C(=C([H])C=1[H])C1C([H])=C([H])C(=C([H])C=1[H])C(N([H])C1=C([H])C([H])=C([H])C(=C1[H])C1=NC([H])([H])C([H])([H])N1[H])=O)N([H])C1=C([H])C([H])=C([H])C(=C1[H])C1=NC([H])([H])C([H])([H])N1[H]
|
Synonyms |
BPH-1358 BPH 1358 BPH1358
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~6.25 mg/mL (~10.39 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.62 mg/mL (1.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 6.2 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 0.62 mg/mL (1.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 6.2 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8918 mL | 9.4588 mL | 18.9175 mL | |
5 mM | 0.3784 mL | 1.8918 mL | 3.7835 mL | |
10 mM | 0.1892 mL | 0.9459 mL | 1.8918 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.